OakChart

Dyne Therapeutics Inc

DYNHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 2:03 PM ET

18.17+0.25 (1.40%)
2026-11-11 20:04 CET
Market cap
3,357.97 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-604.92 USD m
Free cash flow, TTM
-568.76 USD m
EPS diluted, TTM
-3.63
P/E
-
Compare

Price

DYN against its 20, 50 and 200-day averages
2050200beatmiss
15.0020.0025.008.6M17.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DYNclose 18.1720-day 16.8050-day 17.28200-day 19.3318.1752w high52w low

33.5% under the 52-week high of 27.31 on 12 Aug 2026. 52-week low 14.00 on 2 Mar 2026. Last 15 sessions, 24.1% high to low

Profile

DYN
52-week range, 31% of the way up
14.0027.31

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

IndexRUT
Employees258
IPOSep 17, 2020
Beta1.20
ATR, 14d0.94
Rel volume0.44
Short float15.84%
Insider own17.89%
Inst own85.57%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.40B
Enterprise Value2.51B
Income-604.92M
Sales0.00M
Book/sh4.97
Cash/sh6.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees258
IPOSep 17, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.66
P/C3.00
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.99
Current Ratio12.99
Debt/Eq0.26
LT Debt/Eq0.23
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.63
EPS next Y-3.70
EPS next Q-1.00
EPS this Y-9.94%
EPS next Y2.93%
EPS next 5Y4.57%
EPS past 3/5Y-2.41% 3.39%
Sales past 3/5Y- -
EPS Y/Y TTM0.69%
Sales Y/Y TTM-
EPS Q/Q-39.76%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.-16.83% -

Ownership

Insider Own17.89%
Insider Trans-12.45%
Inst Own85.57%
Inst Trans0.71%
ROA-57.56%
ROE-74.56%
ROIC-52.87%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA208.19%
SMA505.14%
SMA200-6.01%
Trades-

Technical

Shs Outstand187.33M
Shs Float153.86M
Short Float15.84%
Short Ratio8.56
Short Interest24.38M
52W High27.31 -33.46%
52W Low14.00 29.79%
Volatility6.70% 5.75%
ATR (14)0.94
RSI (14)56.37
Beta1.20
Rel Volume0.44
Avg Volume2.85M
Volume893,917

Performance

Perf Week-2.00%
Perf Month18.76%
Perf Quarter-30.01%
Perf Half Y-1.46%
Perf YTD-7.11%
Perf Year-7.63%
Perf 3Y108.85%
Perf 5Y27.87%
Perf 10Y-
Recom1.41
Target Price34.33
Prev Close17.92
Price18.17
Change %1.40%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 28, 2026DowngradeOOppenheimerOutperform → Perform$15-17.4%
Sep 09, 2026DowngradeJJP MorganNeutral → Underweight$10-45.0%
Jul 23, 2026InitiatedCCantor FitzgeraldOverweight
Jun 26, 2026InitiatedTTD CowenBuy
Dec 10, 2025UpgradeOOppenheimerPerform → Outperform$40+120.1%
Oct 10, 2025DowngradeOOppenheimerOutperform → Perform
Aug 25, 2025UpgradeRRaymond JamesOutperform → Strong Buy$35+92.6%
Jun 24, 2025InitiatedBBernsteinMkt Perform$13-28.5%
Jun 11, 2025ResumedRRaymond JamesOutperform$37+103.6%
Jun 02, 2025ResumedOOppenheimerOutperform$34+87.1%

Peers

Mkt cap
TickerCompanyMkt cap
SRPTSarepta Therapeutics Inc1.77B
WVEWave Life Sciences Inc675.51M
PEPGPepGen Inc359.56M
TRDAEntrada Therapeutics Inc208.01M
EWTXEdgewise Therapeutics Inc5.19B
SLDBSolid Biosciences Inc852.15M
RGNXRegenxbio Inc577.58M
ARWRArrowhead Pharmaceuticals Inc6.91B
IONSIonis Pharmaceuticals Inc4.81B
CAPRCapricor Therapeutics Inc614.53M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Posner Brian SDirectorOct 02 '26Buy16.002,50040,00027,000Oct 06 04:15 PM
Cox JohnOfficerSep 08 '26Proposed Sale18.885,658106,844Sep 08 04:39 PM
Kerr DouglasOfficerSep 08 '26Proposed Sale18.8935661Sep 08 04:38 PM
Friedl-Naderer JohannaChief Commercial OfficerSep 04 '26Sale24.3590021,915153,082Sep 08 04:15 PM
Friedl-Naderer JohannaChief Commercial OfficerSep 08 '26Sale18.881853,493152,897Sep 08 04:15 PM
Kerr DouglasChief Medical OfficerSep 04 '26Sale24.353,74591,191163,854Sep 08 04:14 PM
Kerr DouglasChief Medical OfficerSep 08 '26Sale18.881,29024,355162,564Sep 08 04:14 PM
Cox JohnCEO & PresidentSep 08 '26Sale18.885,658106,823357,507Sep 08 04:13 PM
Kerr DouglasOfficerSep 04 '26Proposed Sale24.355,000121,745Sep 04 04:02 PM
Rhodes Jason PDirectorAug 14 '26Sale25.002,160,51654,012,900428,946Aug 17 05:30 PM
Rhodes Jason PDirectorAug 13 '26Sale26.20426,41211,171,994751,411Aug 17 05:30 PM
Friedl-Naderer JohannaChief Commercial OfficerAug 13 '26Sale26.282265,939153,982Aug 17 04:08 PM
Kerr DouglasChief Medical OfficerAug 13 '26Sale26.281,55640,892167,599Aug 17 04:08 PM
Cox JohnCEO & PresidentAug 13 '26Sale26.284,986131,032363,165Aug 17 04:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
IBBiShares Biotechnology ETFAUM: 11.36B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.060-0.907-1.0600.000.0016
2026Q22026-07-29-1.080-0.749-1.0790.000.0016
2026Q12026-05-11-0.730-0.772-0.7320.000.0013
2025Q42026-03-02-0.760-0.763-0.7580.000.0014
2025Q32025-11-05-0.760-0.837-0.7620.000.0015
2025Q22025-07-28-0.970-0.942-0.9740.000.0016
2025Q12025-05-08-1.050-0.854-1.0500.000.0014
2024Q42025-02-27-0.880-0.937-0.8750.000.0012
2024Q32024-11-12-0.960-0.712-0.9630.000.0010
2024Q22024-08-12-0.700-0.718-0.7040.000.0010
2024Q12024-05-02-0.810-0.800-0.8100.001.679
2023Q42024-03-05-1.090-0.917-1.0850.000.009
2023Q32023-10-30-0.990-0.833-0.9850.000.008
2023Q22023-08-03-1.080-0.807-1.0850.000.008
2023Q12023-05-11-0.780-0.769-0.7850.000.008
2022Q42023-03-02-0.740-0.845-0.7400.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.130-2.493-4.1290.000.00
2021FY-2.930-2.908-2.9330.000.00
2022FY-3.230-3.350-3.2340.000.00
2023FY-3.950-3.784-3.9530.000.00
2024FY-3.370-3.466-3.3720.000.00
2025FY-3.470-3.502-3.4780.000.00
2026FY--3.815--0.00
2027FY--3.703--44.20
2028FY--3.015--212.47
2029FY--1.926--521.77
2030FY--0.285--969.7

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-079000.000.000.00
2026Q4S2026-11-0510000.000.000.00
2026Q4S2026-09-0410000.000.000.00
2026Q4S2026-08-299000.000.000.00
2026Q4S2026-07-3010000.000.000.00
2026Q4S2026-07-2210000.000.000.00
2026Q4S2026-06-259000.000.000.00
2026Q4S2026-05-118000.000.000.00
2026Q4S2026-03-137000.000.000.00
2026Q4S2026-03-026000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4S2025-11-093000.000.000.00
2026Q4S2025-11-083000.000.000.00

Estimate history

EPS, annual-0.106-0.327-4.129-2.933-3.234-3.953-3.372-3.474-3.6348
Period20182019202020212022202320242025TTM
EPS, quarterly-0.963-0.875-1.05-0.974-0.762-0.758-0.732-1.079-1.065
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual45.42345.42345.07751.56955.63761.469102.319164.951187.328
Period20182019202020212022202320242025MRQ
Shares, quarterly101.753102.319113.634114.339142.613164.951165.201165.671187.328
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.272.052.242.463.351.090.700.270.02
Gross Profit-2.27-2.05-2.24-2.46-3.35-1.09-0.70-0.27-0.02
Selling, General and Administrative Excl. Other617.87466.13341.64239.70167.62148.9457.9513.554.77
Research and Development510.23398.33281.41210.76142.76121.3145.2011.044.28
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-620.14-468.18-343.89-242.16-170.96-150.03-58.65-13.83-4.79
Interest Expense17.946.190.000.000.000.000.400.00-
Unusual Expense0.000.000.000.000.000.000.451.320.02
Net Income Before Taxes-604.92-446.21-317.42-235.94-168.10-149.29-59.44-14.86-4.81
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-604.92-446.21-317.42-235.94-168.10-149.29-59.44-14.86-4.81
Net Income From Continuing Operations-604.92-446.21-317.42-235.94-168.10-149.29-59.44-14.86-4.81
Net Income-604.92-446.21-317.42-235.94-168.10-149.29-59.44-14.86-4.81
EPS (Recurring)-3.33-3.47-3.37-3.95-3.23-2.93-4.11-0.31-0.11
EPS (Basic, Before Extraordinaries)-3.63-3.47-3.37-3.95-3.23-2.93-4.13-0.33-0.11
EPS (Diluted)-3.63-3.47-3.37-3.95-3.23-2.93-4.13-0.33-0.11
EBITDA-617.87-466.13-341.64-239.70-167.62-148.94-57.95-13.55-4.77
Non-Operating Income (Expense)33.1628.1626.476.222.860.730.060.290.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense55.4945.8545.8619.9715.1817.546.590.030.00
Shares Outstanding187.33164.95102.3261.4755.6451.5745.0845.4245.42
Market Capitalization3,357.973,357.972,397.61816.30604.15612.67954.351,004.79-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.600.600.550.520.500.500.501.02
Gross Profit-0.60-0.60-0.55-0.52-0.50-0.50-0.50-1.02
Selling, General and Administrative Excl. Other196.47181.06124.73115.61113.39115.29121.8796.09
Research and Development161.74152.17100.8995.4397.2299.24106.4581.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-197.07-181.66-125.28-116.13-113.89-115.79-122.37-97.11
Interest Expense5.954.594.203.192.900.090.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-193.55-178.56-120.85-111.95-108.04-110.86-115.36-89.54
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-193.55-178.56-120.85-111.95-108.04-110.86-115.36-89.54
Net Income From Continuing Operations-193.55-178.56-120.85-111.95-108.04-110.86-115.36-89.54
Net Income-193.55-178.56-120.85-111.95-108.04-110.86-115.36-89.54
EPS (Recurring)-1.06-1.08-0.73-0.76-0.76-0.97-1.05-0.88
EPS (Basic, Before Extraordinaries)-1.06-1.08-0.73-0.76-0.76-0.97-1.05-0.88
EPS (Diluted)-1.06-1.08-0.73-0.76-0.76-0.97-1.05-0.88
EBITDA-196.47-181.06-124.73-115.61-113.39-115.29-121.87-96.09
Non-Operating Income (Expense)9.477.708.627.378.765.037.017.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.2114.9813.0811.2311.0810.5213.0210.48
Shares Outstanding187.33165.67165.20164.95142.61114.34113.63102.32
Market Capitalization3,357.973,671.622,991.943,164.911,799.641,082.111,183.252,397.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments1,110.56642.27123.10256.01376.57345.3114.638.12
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets16.0217.016.289.585.823.770.130.03
Total Current Assets1,126.59659.28129.38265.59382.39349.0914.768.16
Net Property, Plant & Equipment44.7730.0133.3938.4140.961.951.490.11
Total Investments and Advances15.601.942.312.322.312.300.000.00
Intangible Assets0.000.000.000.000.000.00-0.00
Other Assets0.000.000.000.000.000.000.190.00
Total Assets1,186.96691.23165.08306.32425.66353.3316.448.27
Short Term Debt Incl. Current Port. of LT Debt5.004.854.724.613.890.000.000.00
Accounts Payable8.086.5622.945.264.033.441.260.52
Other Current Liabilities37.5530.8523.4418.2220.807.531.100.19
Total Current Liabilities50.6242.2651.0928.0928.7210.972.360.71
Long Term Debt164.2019.1422.7025.8728.740.000.003.38
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.040.00
Total Liabilities214.8361.4073.7953.9657.4710.972.404.09
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0027.439.06
Common Equity972.13629.8491.29252.36368.20342.37-13.39-4.88
Total Shareholders Equity972.13629.8491.29252.36368.20342.3714.044.18
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity972.13629.8491.29252.36368.20342.3714.044.18
Total Liabilities & Stockholders Equity1,186.96691.23165.08306.32425.66353.3316.448.27
Book Value Per Share5.896.161.494.547.147.60-0.29-0.11
Tangible Book Value Per Share5.896.161.494.547.147.60-0.29-0.11
Full-Time Employees2581911411239547--
Price to Book Ratio3.613.405.362.411.672.762.71-
Return on Assets-47.52-74.14-100.10-45.93-38.33-32.15-120.30-
Return on Equity-55.71-88.03-137.31-54.18-42.02-33.35-163.12-
Return on Invested Capital-39.27-48.91-206.99-60.42-37.61-17.36-105.86-63.66
Quick Ratio22.2515.602.539.4613.3131.836.2611.47
Current Ratio22.2515.602.539.4613.3131.836.2611.47

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-604.92-446.21-317.42-235.94-168.10-149.29-59.44-14.86-4.81
Depreciation2.272.052.242.463.351.090.700.270.02
Other Funds (Non Cash)55.1944.3642.3019.0116.4919.387.121.350.02
Funds from Operations-547.46-399.80-272.88-214.47-148.27-128.82-51.62-13.24-4.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-17.07-3.40-19.4926.31-5.389.265.111.410.60
Cash from Operating Activities-564.53-403.21-292.37-188.16-153.65-119.56-46.51-11.83-4.16
Capital Expenditures-4.23-20.71-2.38-0.73-3.07-3.62-1.16-1.65-0.13
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-3.27-8.04-201.7084.0490.27-134.27-44.500.000.00
Purchase of Investments-185.33-180.53-317.44-44.26-121.18-236.72-44.500.000.00
Sale Or Maturity of Investments182.06172.49115.74128.30211.44102.450.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-7.50-28.75-204.0883.3187.20-137.89-45.66-1.65-0.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock790.08742.61809.8954.3237.39157.82381.2019.9912.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock790.08742.61809.8954.3237.39157.82381.2019.9912.42
Proceedsfrom Stock Options377.73734.61773.0552.3736.860.00381.1719.9912.42
Issuance or Reduction of Debt, Net124.17147.700.000.000.000.00-0.060.000.00
Change in Long Term Debt98.81147.700.000.000.000.00-0.060.000.00
Issuance of Long Term Debt98.81147.700.000.000.000.009.940.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-10.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.450.000.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.450.000.00
Cash from Financing Activities914.24890.31809.8954.3237.39157.82380.6919.9912.42
Net Change in Cash342.21458.35313.45-50.52-29.05-99.63288.526.518.12
Free Cash Flow-568.76-423.92-294.75-188.89-156.71-123.18-47.67-13.48-4.30
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,134.39898.48972.161,110.56791.89683.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets41.6439.4148.8716.0214.3814.03
Total Current Assets1,176.03937.891,021.031,126.59806.26697.95
Net Property, Plant & Equipment26.1744.8143.3344.7745.7928.53
Total Investments and Advances32.6011.3115.5915.6015.012.51
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets1,234.80994.011,079.951,186.96867.06728.99
Short Term Debt Incl. Current Port. of LT Debt30.9619.5211.265.005.045.00
Accounts Payable14.9012.1510.788.0812.0614.02
Other Current Liabilities44.6946.3629.2137.5542.7522.45
Total Current Liabilities90.5578.0351.2550.6259.8541.47
Long Term Debt213.32213.83163.65164.20115.43116.08
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities303.87291.86214.90214.83175.28157.55
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity930.93702.15865.05972.13691.78571.45
Total Shareholders Equity930.93702.15865.05972.13691.78571.45
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity930.93702.15865.05972.13691.78571.45
Total Liabilities & Stockholders Equity1,234.80994.011,079.951,186.96867.06728.99
Book Value Per Share4.974.245.245.894.855.00
Tangible Book Value Per Share4.974.245.245.894.855.00
Full-Time Employees322289-258240206
Price to Book Ratio3.614.243.084.032.531.62
Return on Assets-57.56-60.29-50.16-47.52-51.81-53.11
Return on Equity-74.56-81.57-58.89-55.71-60.66-61.32
Return on Invested Capital-16.92-19.49-11.75-9.85-13.38-16.12
Quick Ratio12.9912.0219.9222.2513.4716.83
Current Ratio12.9912.0219.9222.2513.4716.83

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-193.55-178.56-120.85-111.95-108.04-110.86
Depreciation0.640.560.550.520.520.50
Other Funds (Non Cash)16.3614.9113.0110.9110.8710.01
Funds from Operations-176.55-163.08-107.30-100.52-96.65-100.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.9432.80-37.62-11.315.875.64
Cash from Operating Activities-177.49-130.29-144.92-111.83-90.78-94.70
Capital Expenditures-2.01-1.51-0.22-0.48-19.18-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.72-3.28-2.171.47-18.786.83
Purchase of Investments-51.56-42.79-64.28-26.71-46.92-40.93
Sale Or Maturity of Investments52.2739.5162.1128.1828.1447.77
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.29-4.79-2.390.98-37.976.77
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock406.930.740.89381.52217.881.97
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock406.930.740.89381.52217.881.97
Proceedsfrom Stock Options0.000.00-0.42378.15215.800.00
Issuance or Reduction of Debt, Net11.1757.346.2149.45-0.5598.80
Change in Long Term Debt-0.0649.420.0049.45-0.5598.80
Issuance of Long Term Debt-0.0649.420.0049.45-0.5598.80
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities418.1058.117.06430.96217.33100.77
Net Change in Cash239.32-76.97-140.25320.1288.5812.85
Free Cash Flow-179.50-131.80-145.14-112.32-109.96-94.76

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.84%24.4M153.9M2.76M
2026-10-1516.61%25.5M153.3M2.92M
2026-09-3016.52%26.0M157.2M2.68M
2026-09-1514.87%23.4M157.2M2.66M
2026-08-3113.56%20.8M153.3M2.21M
2026-08-1414.00%21.5M153.3M2.22M
2026-07-3114.42%22.0M152.3M2.10M
2026-07-1515.95%21.5M134.8M1.85M
2026-06-3016.67%22.3M133.8M1.79M
2026-06-1517.20%22.8M132.6M1.75M
2026-05-2916.88%22.3M132.0M1.96M
2026-05-1515.90%21.0M132.0M2.02M
2026-04-3016.02%20.7M129.4M2.10M
2026-04-1517.03%21.7M127.5M2.15M
2026-03-3117.04%20.5M120.1M2.26M
2026-03-1315.90%19.1M120.1M2.17M
2026-02-2716.08%19.3M120.1M2.41M
2026-02-1316.26%19.2M117.8M2.48M
2026-01-3015.46%19.2M124.1M2.66M
2026-01-1515.22%18.9M124.1M2.85M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call9.007.0011.500.007.3730.000.000.982-0.0180.001
call10.006.0010.508.686.6110.000.000.979-0.0170.001
call11.005.009.000.005.1230.000.000.976-0.0170.002
call12.004.008.400.005.0700.000.000.972-0.0170.002
call13.003.007.502.404.6701.000.000.850-0.0980.007
call14.002.006.500.004.1690.000.000.824-0.0910.007
call15.001.104.902.952.9329190.000.795-0.0850.008
call16.000.503.403.001.9662,0530.000.753-0.0760.009
call17.001.201.701.140.9755,3400.000.643-0.1300.011
call18.000.751.150.050.90914,0336.000.598-0.1730.011
call19.000.003.302.251.28415.000.000.512-0.1280.011
call20.000.001.950.351.59819.000.000.407-0.1010.011
call21.000.002.750.001.8600.000.000.368-0.1120.011
call22.000.004.900.002.0960.000.000.341-0.1230.010
call23.000.000.800.001.9450.000.000.268-0.0960.010
call24.000.003.100.002.1310.000.000.256-0.1100.009
call25.000.000.250.151.5671.000.000.122-0.0480.006
call26.000.003.200.001.7080.000.000.117-0.0540.006
put9.000.004.900.052.3506.000.00-0.018-0.0160.001
put10.000.001.450.003.9410.000.00-0.105-0.1120.005
put11.000.002.750.003.4530.000.00-0.120-0.1080.006
put12.000.000.050.053.0052.000.00-0.138-0.1030.006
put13.000.002.750.452.5941.000.00-0.150-0.0960.007
put14.000.002.751.002.18375.000.00-0.176-0.0890.007
put15.000.000.750.051.8427220.00-0.205-0.0830.008
put16.000.000.700.701.4811410.00-0.247-0.0740.009
put17.000.002.101.202.4273470.00-0.354-0.1270.011
put18.000.004.701.004.22052.000.00-0.404-0.1660.011
put19.000.154.900.003.6510.000.00-0.497-0.1230.011
put20.000.204.900.003.0670.000.00-0.599-0.0980.011
put21.000.904.600.002.4560.000.00-0.634-0.1110.011
put22.001.806.400.003.4630.000.00-0.658-0.1200.011
put23.002.806.800.003.1570.000.00-0.728-0.1010.009
put24.004.408.400.003.8990.000.00-0.743-0.1070.009
put25.004.909.400.004.0660.000.00-0.876-0.0490.006
put26.005.9010.300.004.1550.000.00-0.883-0.0510.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-06SCHEDULE 13G/ASEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1040.00K100
2026-0900247.78K5
2026-080065.41M6
2026-070024.53M3
2026-0677.58K223.64M13
2026-0579.22K22.06M7
2026-040036.93M14
2026-03118.04K315.74M6
2026-020000
2026-010000
2025-120076.37K3
2025-110000

Institutional holders

Manager% owned
T. Rowe Price Investment Management, Inc.18.70%
BlackRock, Inc.7.50%
Jupiter Topco LLC7.26%
FMR LLC5.97%
STATE STREET CORP4.51%
Orbis Allan Gray Ltd4.24%
VANGUARD CAPITAL MANAGEMENT LLC3.82%
TCG Crossover Management, LLC2.79%
VANGUARD PORTFOLIO MANAGEMENT LLC2.45%
PRICE T ROWE ASSOCIATES INC /MD/2.38%

Funds

Fund% owned
T. Rowe Price Small-Cap Stock Fund, Inc.4.24%
T. Rowe Price Small-Cap Value Fund, Inc.2.78%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.51%
T. Rowe Price Institutional Small-Cap Stock Fund2.30%
iShares Russell 2000 ETF2.15%
T. Rowe Price Capital Appreciation Fund1.98%
Fidelity Growth Company Fund1.69%
VANGUARD HEALTH CARE FUND1.53%
Janus Henderson Global Life Sciences Fund1.37%

OakChart. DYN. Cached 15 minutes.